AmerisourceBergen Foundation launches support program combating opioid abuse
The AmerisourceBergen Foundation has announced the launch of a municipal support program aimed towards the safe disposal of opioids. The Valley Forge, Pa.-based company aims to do this by providing communities nationwide with resources to deactivate expired or unused medications.
“The epidemic of opioid abuse demands action, attention and a collaborative approach. The safe disposal of unused prescription medications is a critical component in combating the issue, as it reduces the risk for misuse, abuse, and diversion,” Gina Clark, president of the AmerisourceBergen Foundation, and executive vice president and chief communications & administration officer at AmerisourceBergen said. “At AmerisourceBergen and the AmerisourceBergen Foundation, we are united in our responsibility to create healthier futures. Through this program, we will provide communities with the resources needed to deactivate prescription medications in a safe and effective manner, and help advance their efforts to prevent opioid abuse.”
As part of the program, the AmerisourceBergen Foundation will distribute drug deactivation resources to municipalities that are actively working to prevent opioid abuse and misuse, the company said. These disposable resources will use a technology that will deactivate opioids when combined with water.
In order to support these efforts, AmerisourceBergen will leverage its network of distribution centers to provide communities across the country with access to the drug deactivation resources. More information about the program and foundation can be found on the company’s website.
Pfizer gets FDA nod for second Remicade biosimilar
The Food and Drug Administration recently approved Pfizer’s Ixifi (infliximab-qbtx), the company’s second approved biosimilar of Janssen’s Remicade. The biosimilar was approved for all of Remicade’s indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis, among others.
The approval follows the April 2016 launch of its first Remicade biosimilar Inflectra. According to reports, Pfizer has said it has no plans to launch Ixifi in the United States.
Outside the United States, Pfizer markets Inflectra, Retacrit (epoetin zeta) and Nivestim (filgrastim). It said that its biosimilars pipeline includes 13 distinct biosimilar molecules in various stages of development.
Teva’s generic Viread launches
Tevs has introduced its exclusive generic of Gilead’s Viread (tenofovir disoproxil fumarate), the company announced Friday. The drug is indicated to treat HIVE in adults and pediatric patients ages 2 years old and older, as well as chronic hepatitis B in patients ages 12 years old and older.
“Currently, 1.1 million people in the U.S are living with HIV and an estimated 850,000 to 2.2 million have chronic hepatitis B virus infection,” Teva executive vice president of North America commercial Brendan O’Grady said. “The launch of generic Viread is an important addition to our portfolio; but, more importantly, it brings an effective, affordable treatment option to these patients in an area that’s lacking.”
Teva’s generic will be available in 300-mg dosage strength tablets. The product had U.S. sales of roughly $762 million for the 12 months ended October 2017, according to IQVIA data.